Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Lipid science receives new Australia-led online hub

The Lipid Network launched this month to build links between researchers, clinicians and industry...

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

Content from other channels on our network

Vessev launches an electric hydrofoiling network in Tas

Office tower cuts HVAC energy use by nearly 50%

Climate Tech Partners backs Australian battery recycling

Cost greater to abandon net zero transition, say G7 leaders

American microbiologist wins 2026 Lee Kuan Yew Water Prize

Nestlé partners on nutrition research targeted for women's health

Next-gen pumps use film-based technology

ARBS 2026 seminar program unveiled

Boosting food security ahead of the 2032 Summer Olympics

Antiviral plastic film for surfaces developed at RMIT

WA Government extends support for lithium industry

Manufacturing-friendly plastic surface destroys viruses on contact

Queensland Government reports progress on Energy Roadmap after six months

Government fast-tracks funding to support industry and shore up supply chains

AI won’t restart your plant: Why practical skills matter more than ever